Page 10 - Diabetic Kidney News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 surrounding a comprehensive panel of novel biomarkers in kidney disease
 
NEW YORK, April 14, 2021
 -
Renalytix AI plc
(LSE: RENX) (NASDAQ: RNLX) announced today that it has entered into an exclusive option agreement with Joslin Diabetes Center for patent filings on certain additional novel biomarkers in kidney disease for development and deployment in the KidneyIntelX in vitro prognostic platform.
 
These novel biomarkers have the potential to provide additional clinical utility for understanding early disease progression and risk of kidney failure, therapeutic response, and the mechanistic pathways of kidney disease beyond the inflammatory and tubular injury markers that are currently captured by KidneyIntelX. RenalytixAI plans to begin evaluating these novel biomarkers in expanded clinical validation studies beginning in the second half of 2021.  ....

United States , Paul Mcmanus Lianne Cawthorne , James Mccullough , Fergus Fleming , Nicholas Moore , Alex Price , Roberta Herman , Daniel Adams , Andrzej Krolewski , Gary Clarence , Centers For Disease , Exchange Commission , Joslin Diabetes Center , Drug Administration , Harvard Medical School , Investec Bank , Joslin Diabetes Center Build , Proprietary Kidney Biomarker , Chief Technology Officer , Joslin Diabetes , Section Head , Senior Investigator , Diabetic Kidney , Nominated Adviser , Joint Broker , Kidney Disease ,